Status:
RECRUITING
Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis
Lead Sponsor:
Medical University of Vienna
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Optic Neuritis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Multiple sclerosis (MS) affects approximately 2.3 million patients worldwide, with a global median prevalence of 33 per 100,000. MS is diagnosed at an average of 30 years and affects twice as many wom...
Eligibility Criteria
Inclusion
- Inclusion criteria for healthy subjects:
- Men and women aged over 18 years
- Non-smokers
- Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
- Normal ophthalmic findings, ametropy \< 6 Dpt.
- Inclusion criteria for patients with MS:
- Men and women aged over 18 years
- Diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to clinical evaluation and McDonald criteria (revision 2010)
- History of AON in one eye at least one year ago
- Non-smokers
- Normal ophthalmic findings, ametropy \< 6 Dpt.
- Adequate visual acuity to allow participation in the ocular blood flow measurements
- A potential participant has to be on stable doses of all medications he/she is taking because of consisting illnesses according to medical history (except MS therapy itself which will be recorded separately) for at least 30 days prior inclusion, if considered relevant by the investigator.
- Any of the following will exclude a healthy subject from the study:
- Diagnosis of "possible MS" according to the McDonald criteria (revision 2010)
- Presence or history of a severe medical condition as judged by the clinical investigator
- Untreated Arterial hypertension
- History or family history of epilepsy
- Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
- Family history of MS, optic neuritis, neuromyelitis optica (NMO, Devic disease) or NMO spectrum disorders
- History of inflammatory or infectious disease of central nervous system
- Best corrected visual acuity \< 0.5 Snellen
- Ametropy ≥ 6Dpt
- Pregnancy or planned pregnancy
- Alcoholism or substance abuse
- Any of the following will exclude a patient from the study:
- Presence or history of a severe medical condition other than MS as judged by the clinical investigator
- History of neuromyelitis optica (NMO, Devic disease) or NMO spectrum disorders
- History of inflammatory or infectious disease of central nervous system other than MS
- Untreated Arterial hypertension
- History or family history of epilepsy
- Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
- Best corrected visual acuity \< 0.5 Snellen
- Ametropy ≥ 6 Dpt
- Pregnancy, planned pregnancy
- Significant neurological disease other than MS, if considered relevant by the investigator
- Alcoholism or substance abuse
Exclusion
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03401879
Start Date
February 1 2018
End Date
March 1 2026
Last Update
May 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Pharmacology, Medical University of Vienna
Vienna, Austria, Austria, 1090